Institute of Hematology, Clinical Center of Serbia, str Koste Todorovica 2, Belgrade, Serbia.
Med Oncol. 2011 Mar;28(1):237-40. doi: 10.1007/s12032-010-9432-4. Epub 2010 Feb 2.
The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in comparison with standard prognostic parameters β(2)-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in serum level of ICTP (P = 0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant predictor of osteolysis (P = 0.09), while CRP is the most significant risk factor for overall survival (P < 0.01). Being highly significant predictor of osteolysis, ICTP can be used for identification of patients with MM who had increased risk for developing osteolytic lesions.
I 型胶原羧基末端肽(ICTP)的降解产物代表了一种新的生化参数,反映了骨骼系统吸收特性的变化。骨骼的改变是多发性骨髓瘤(MM)的最重要特征之一。我们通过比较 ICTP 与标准预后参数β(2)-微球蛋白和 C 反应蛋白(CRP),评估了 ICTP 作为溶骨性标志物和总体生存率在 MM 患者中的意义。我们的研究结果表明,在常规 X 光片上有或无溶骨性病变的患者的 ICTP 血清水平存在显著差异(P=0.009)。结果证明 ICTP 是溶骨性病变的最显著预测因子(P=0.09),而 CRP 是总体生存率的最显著危险因素(P<0.01)。作为溶骨性的高度显著预测因子,ICTP 可用于识别具有增加发生溶骨性病变风险的 MM 患者。